bamlanivimab
Sign in to saveAlso known as LY3819253, LY-CoV555
Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The medication was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and the EUA was revoked in April 2021.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- Spike protein of SARS-CoV-2
- Drug.DailyMedID
- Bamlanivimab
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- None
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_US
- Rx-only
- Drug.legal_US_comment
- via emergency use authorization
- Drug.CAS_number
- 2423943-37-5
- Drug.DrugBank
- DB15718
- Drug.UNII
- 45I6OFJ8QH
- Drug.KEGG
- D11936
- Drug.synonyms
- LY-CoV555, LY3819253
via Wikipedia infobox
~5 min read
Encyclopedic overview
12 sectionsContents
- Studies
- Animal trials
- Human trials
- BLAZE-1 Trial
- ACTIV-2 Trial
- ACTIV-3 Trial
- Authorization
- Bamlanivimab/etesevimab
- Deployment
- Society and culture
- Names
- References
Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The medication was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and the EUA was revoked in April 2021.
Bamlanivimab is an IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. The aim is to block viral attachment and entry into human cells, thus neutralizing the virus, and help preventing and treating COVID-19.
Excerpted from Wikipedia’s “bamlanivimab” article, available under the CC BY-SA 4.0 licence.